-
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Wortelboer, N., Kent, S., Konings, I. R., van Ommen-Nijhof, A., van der Noort, V., van den Pol, E., Guerrero Páez, C., van Bekkum, M. L., van den Berkmortel, F. W. P. J., Droogendijk, H. J., Houtsma, D., Oosterkamp, H. M., van der Padt-Pruijsten, A., Siemerink, E. J. M., Tol, J., van Zweeden, A. A., van Leeuwen-Stok, A. E., Sonke, G. S., Jager, A. & Blommestein, H. M., 9 Dec 2025, In: Eur. J. Cancer. 231, 116051.Research output: Contribution to journal › Article › Academic › peer-review
-
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
Jongbloed, E. M., Wortelboer, N., de Weerd, V., Beaufort, C. M., Ruigrok-Ritstier, K., van, M. N., Kraan, J., van Zweeden, A. A., van der Padt-Pruijsten, A., Hamming, L. C., Konings, I. R., Sonke, G. S., Oomen-de Hoop, E., Martens, J. W. M., Jager, A. & Wilting, S. M., Nov 2025, In: Nature Medicine. 31, 11, p. 3662-3667 6 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer
van Hemert, A. K. E., van Loevezijn, A. A., Baas, M.-S. P. D., Stokkel, M. P. M., Groen, E. J., van der Noort, V., Loo, C. E., Sonke, G. S., Russell, N., van Duijnhoven, F. H. & Vrancken Peeters, M.-J. T. F. D., 16 Oct 2025, In: JAMA oncology. 11, 10, p. 1204-1211 8 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
